A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose
(MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when
administered orally once daily to adult patients with Multiple Myeloma (MM).